Cargando…

Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result

Background: This study aimed to develop and internally validate computed tomography (CT)-based radiomic models to predict the lesion-level short-term response to tyrosine kinase inhibitors (TKIs) in patients with advanced renal cell carcinoma (RCC). Methods: This retrospective study included consecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuntian, Yuan, Enyu, Sun, Guangxi, Song, Bin, Yao, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966873/
https://www.ncbi.nlm.nih.gov/pubmed/36835837
http://dx.doi.org/10.3390/jcm12041301
_version_ 1784897124715986944
author Chen, Yuntian
Yuan, Enyu
Sun, Guangxi
Song, Bin
Yao, Jin
author_facet Chen, Yuntian
Yuan, Enyu
Sun, Guangxi
Song, Bin
Yao, Jin
author_sort Chen, Yuntian
collection PubMed
description Background: This study aimed to develop and internally validate computed tomography (CT)-based radiomic models to predict the lesion-level short-term response to tyrosine kinase inhibitors (TKIs) in patients with advanced renal cell carcinoma (RCC). Methods: This retrospective study included consecutive patients with RCC that were treated using TKIs as the first-line treatment. Radiomic features were extracted from noncontrast (NC) and arterial-phase (AP) CT images. The model performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). Results: A total of 36 patients with 131 measurable lesions were enrolled (training: validation = 91: 40). The model with five delta features achieved the best discrimination capability with AUC values of 0.940 (95% CI, 0.890‒0.990) in the training cohort and 0.916 (95% CI, 0.828‒1.000) in the validation cohort. Only the delta model was well calibrated. The DCA showed that the net benefit of the delta model was greater than that of the other radiomic models, as well as that of the treat-all and treat-none criteria. Conclusions: Models based on CT delta radiomic features may help predict the short-term response to TKIs in patients with advanced RCC and aid in lesion stratification for potential treatments.
format Online
Article
Text
id pubmed-9966873
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99668732023-02-26 Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result Chen, Yuntian Yuan, Enyu Sun, Guangxi Song, Bin Yao, Jin J Clin Med Article Background: This study aimed to develop and internally validate computed tomography (CT)-based radiomic models to predict the lesion-level short-term response to tyrosine kinase inhibitors (TKIs) in patients with advanced renal cell carcinoma (RCC). Methods: This retrospective study included consecutive patients with RCC that were treated using TKIs as the first-line treatment. Radiomic features were extracted from noncontrast (NC) and arterial-phase (AP) CT images. The model performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). Results: A total of 36 patients with 131 measurable lesions were enrolled (training: validation = 91: 40). The model with five delta features achieved the best discrimination capability with AUC values of 0.940 (95% CI, 0.890‒0.990) in the training cohort and 0.916 (95% CI, 0.828‒1.000) in the validation cohort. Only the delta model was well calibrated. The DCA showed that the net benefit of the delta model was greater than that of the other radiomic models, as well as that of the treat-all and treat-none criteria. Conclusions: Models based on CT delta radiomic features may help predict the short-term response to TKIs in patients with advanced RCC and aid in lesion stratification for potential treatments. MDPI 2023-02-06 /pmc/articles/PMC9966873/ /pubmed/36835837 http://dx.doi.org/10.3390/jcm12041301 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Yuntian
Yuan, Enyu
Sun, Guangxi
Song, Bin
Yao, Jin
Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
title Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
title_full Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
title_fullStr Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
title_full_unstemmed Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
title_short Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
title_sort delta radiomics model predicts lesion-level responses to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: a preliminary result
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966873/
https://www.ncbi.nlm.nih.gov/pubmed/36835837
http://dx.doi.org/10.3390/jcm12041301
work_keys_str_mv AT chenyuntian deltaradiomicsmodelpredictslesionlevelresponsestotyrosinekinaseinhibitorsinpatientswithadvancedrenalcellcarcinomaapreliminaryresult
AT yuanenyu deltaradiomicsmodelpredictslesionlevelresponsestotyrosinekinaseinhibitorsinpatientswithadvancedrenalcellcarcinomaapreliminaryresult
AT sunguangxi deltaradiomicsmodelpredictslesionlevelresponsestotyrosinekinaseinhibitorsinpatientswithadvancedrenalcellcarcinomaapreliminaryresult
AT songbin deltaradiomicsmodelpredictslesionlevelresponsestotyrosinekinaseinhibitorsinpatientswithadvancedrenalcellcarcinomaapreliminaryresult
AT yaojin deltaradiomicsmodelpredictslesionlevelresponsestotyrosinekinaseinhibitorsinpatientswithadvancedrenalcellcarcinomaapreliminaryresult